GVR Report cover Cellular Health Screening Market Size, Share & Trends Report

Cellular Health Screening Market Size, Share & Trends Analysis Report By Test Type (Single Test Panels, Multi-test Panels), By Sample Test (Blood, Saliva) By Collection Sites (Home, Hospitals), And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-3-68038-972-2
  • Number of Pages: 130
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2020
  • Industry: Healthcare

Report Overview

The global cellular health screening market size was valued at USD 2.22 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2021 to 2028. Cellular health screening facilitates easy and rapid understanding of one’s health at a cellular level. This technology helps in identifying areas that need immediate support and enables professionals to develop an individualized plan to achieve effective results. Due to the COVID-19 pandemic, market players witnessed a decline in their sales and base testing volume. Moreover, the supply chain is disrupted due to governmental impositions and restrictions on transportation, export, and import of products, raw materials, etc. during the pandemic. This has led to a decrease in the demand; many of the organizations have diversified their product portfolios from cellular health testing line to COVID-19 molecular and antibody testing, which can equally offset the decrease in base testing volume.

U.S. cellular health screening market size, by test type, 2016 - 2028 (USD Million)

Applications of home-based diagnostic tests are significantly increasing globally. Public awareness campaigns aimed at identifying the symptoms of chronic diseases and ways to prevent them play an important role in controlling the spread of the disease. Thus, increased patient awareness has led to high demand for cellular health screening kits and services. The use of these devices also eliminates the need to wait for deciphering test results as well as aids in optimization of timely treatment decision, improves the efficacy of care provided, and significantly reduces diagnosis cost, especially in resource-constrained settings where laboratory infrastructure is weak.

Several research studies are indicative of the correlation between cancers and telomere length. Telomere shortening as a tumor suppressor proves to be a major factor in aggravated forms of cancer. Although it has been established that the length of telomeres is influenced by a variety of factors, such as infections, inflammation, and stress, these factors, particularly inflammation, resulting in oxidative stress, leading to telomere erosion.

Research supports telomere maintenance to being a major element for effects of environmental, lifestyle, and genetic issues on aging and related diseases. Therefore, the rate of telomere change facilitates a vital understanding of biological aging and genetic diseases. Furthermore, a decline of telomere length has been linked to age-related pathological issues, including Cardiovascular Diseases (CVDs), cancer, and reduced immune function. Thus, with the rising incidence of chronic diseases, the demand for cellular health screening is likely to increase in the coming years.

The rising number of programs by various organizations aimed at increasing awareness about preventive healthcare-based testing products and services will also augment market growth. Furthermore, collaborations, such as those undertaken by the CDC, National Cervical Cancer Coalition, the U.S. Preventive Services Task Force (USPSTF), WHO, and others, for cervical cancer screening are expected to boost the market growth during the forecast period. In addition, major market players are undertaking initiatives to increase awareness about cervical and vaginal cancer screening.

Cellular Health Screening Market Trends

Increasing number of awareness programs by organizations across the globe has led to a growing need for preventive healthcare-based testing solutions. Collaborative initiatives undertaken by institutions such as the WHO, CDC, the U.S. Preventive Services Task Force, and National Cervical Cancer Coalition, among others, for promotion of cervical cancer screening, is one of the major factors expected to drive the market growth in the near future.

Similarly, several countries and local governments have undertaken measures for promoting screening of the most diagnosed cancers in their respective regions. For instance, in the U.S., the Georgia Department of Public Health offers breast and cervical cancer screening services to uninsured women living in Georgia. Similarly, the Indian government has initiated the Ayushman Bharat and the Prime Minister’s National Relief Fund (PMNRF) for patients that require assistance during cancer treatment. Such initiatives can increase the adoption of cellular health screening services and boost the market.

Home-based diagnostic tests are gaining traction globally, due to increased patient awareness about cellular health screening kits and services. These devices aid in achieving timely treatment decisions by eliminating the long waiting time for arrival of test results. This also improves the efficacy of care provided, and can lead to cost reduction, especially in areas with limited availability of resources. Furthermore, increasing trend toward decentralization of testing has been crucial in increasing the adoption of such devices globally.

As most diseases are linked to some form of genetic basis, various diagnostic companies have used technological advancements to develop genetic tests directly for consumers. For instance, in September 2021, MedGenome Labs, introduced its direct-to-consumer category in India, with the launch of Kardiogen and Curegen personal genomics tests. Such kits are typically targeted toward individuals that are not necessarily at high disease risk or ill but are curious to understand their risk for various diseases and disorders.

Although there has been a significant rise in direct-to-consumer genetic testing, several issues with sample transportation are anticipated to negatively impact the market growth. Some of the major factor affecting the performance of these tests is the quantity and quality of DNA extracted. Some of the causes for failure of quality DNA extraction include blood clotting, owing to poor mixing with anticoagulants like EDTA, the use of serum tubes, and delays in sample transport. These factors may hamper the market growth in the near future.

There are several genetic testing kits that are commercially available in the market, although pricing variations for the same test by different manufacturers are a factor anticipated to hamper market growth. Genetic tests are usually priced between USD 100 and USD 2,000, based on the complexity of tests. Tests that determine the probability of chronic and life-threatening diseases such as cancer are typically covered by insurance; however, cellular health screening tests may often be an out-of-pocket expense for most consumers. Inconclusive tests may also prove to be a factor limiting the uptake of such tests.

Test Type Insights

The single test panels segment dominated the market in 2020 with a revenue share of 80.18%. The single test panels segment is further segmented into telomere, oxidative stress, inflammation, and heavy metal tests. The telomere sub-segment held the highest share in this market. These panels provide accurate data and aid in performing efficient screening tests to measure the length of the telomere, thereby preventing diseases. Hence, increasing demand for preventive healthcare screening products and services is anticipated to boost the market growth.

The multi-test panels segment is projected to register the fastest CAGR during the forecast period. The market inclination toward multi-test panels is rising since they offer results for multiple biomarkers in a single exam. They have multiple advantages, such as advanced diagnostic precision, enhanced diagnostic competence, and reduced diagnostic cost.

Sample Test Insights

The blood sample segment held the dominant market share of 48.15% in 2020, as blood samples are most frequently used by clinicians to evaluate organ functions, diagnose diseases & conditions, analyze risk factors, determine medicinal efficacy, and assess blood clotting. In addition, the introduction of new blood-based cellular health screening tests has further supported the segment growth. For instance, in 2018, LabCorp Holdings introduced a blood-testing device that can be used at home to perform cellular health screening tests.

The urine sample segment also accounted for a significant market share as it is a quicker, patient-friendly, and less invasive sample to collect. Genova Diagnostics offers Oxidative Stress Analysis 2.0 that evaluates oxidative stress status in the body. This test uses urine as a sample to detect two key biomarkers - lipid peroxides and 8-OHdG - that cause oxidative stress damage. Thus, the increasing prevalence of oxidative stress is also expected to boost segment growth during the forecast period.

Collection Sites Insights

The hospitals segment dominated the market with a share of 39.33% in 2020. Hospitals facilitate primary treatment and diagnostics for a majority of the population. Diagnostic tests related to cellular health screening for most of the in-patient population are typically conducted in hospitals and clinics as physicians recommend reliable diagnostic processes for testing as well as sample collection. Thus, the hospitals segment is expected to have significant growth over the coming years. Moreover, the availability of trained professionals facilitating easy and safe sample collection and testing processes will also support the segment growth.

Global cellular health screening market share, by collection sites, 2020 (%)

Home collection sites is projected to register the fastest CAGR from 2021 to 2028 owing to the increasing adoption of self-sampling in key markets as it is user-friendly and does not require specialized lab infrastructure and professional training. The global COVID-19 pandemic has further supported the home collection segment due to lockdowns and movement restrictions in the major economies.

Regional Insights

North America held the largest share accounting for about 47% of the market value in 2021 and is expected to grow at a rapid rate throughout the forecast period. Rising awareness about Healthy Life Expectancy (HALE), growing chronic disease burden, and increasing government focus on preventive healthcare are some of the major factors anticipated to drive the market growth in the region. The U.S. held the maximum share in the regional market due to the presence of key market players, increasing availability of telomere & oxidative stress tests, rising adoption of at-home testing options, and growth in awareness about rare diseases.

Canada cellular health screening market is anticipated to witness growth over the forecast period owing to developments in its healthcare infrastructure and increasing healthcare expenditure. Canada has one of the most aged population, along with Italy and Japan, as over 20.0% of the country’s population is estimated to be 65+ by 2026. Increasing prevalence of diseases among geriatric population has necessitated regular screening of cellular health, as early treatment can decrease the chances of fatality. These factors can lead to lucrative growth of the market in Canada.  

In Singapore, cellular health screening market is expected witness growth over the forecast period. According to WHO, the country’s healthcare system ranks sixth and provides the fourth best healthcare infrastructure globally, which is expected to positively affect the market growth. Rising investments by the government to facilitate R&D in the field of infectious diseases have been key in facilitating growth. Similarly, rising R&D in genomics and genetic engineering is a key factor anticipated to further fuel the demand for these diagnostic devices in the country.

Key Companies & Market Share Insights

The market includes a large number of well-established and emerging players. These players are adopting various strategies, such as the launch of new products, collaborations, geographical expansion, and partnerships, to strengthen their position in the market. For instance, in October 2016, Telomere Diagnostics launched TeloYears, which helps in monitoring the vitality of cells based on telomere length. Some prominent players in the global cellular health screening market include:

  • Telomere Diagnostics

  • SpectraCell Laboratories

  • Life Length

  • Repeat Diagnostics, Inc.

  • Cell Science Systems Corp.

  • Quest Diagnostics

  • LabCorp Holdings

  • OPKO

  • Genova Diagnostics

  • Immunodiagnostik AG

  • DNA Labs

Cellular Health Screening Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 2.26 billion

Revenue forecast in 2028

USD 3.47 billion

Growth rate

CAGR of 6.3% from 2021 to 2028

Base year for estimation

2020

Historical data

2016 - 2020

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Test type, sample test, collection sites, and region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Spain; France; Italy; Russia; China; India; Japan; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Telomere Diagnostics; SpectraCell Laboratories; Life Length; Repeat Diagnostics, Inc.; Cell Science Systems Corp.; Quest Diagnostics; LabCorp Holdings; OPKO; Genova Diagnostics; Immunodiagnostik AG; DNA Labs

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global cellular health screening market report on the basis of test type, sample test, collection sites, and region:

  • Test Type Outlook (Revenue, USD Million, 2016 - 2028)

    • Single Test Panels

      • Telomere Tests

      • Oxidative Stress Tests

      • Inflammation Tests

      • Heavy Metals Tests

    • Multi-test Panels

  • Sample Test Outlook (Revenue, USD Million, 2016 - 2028)

    • Blood

    • Saliva

    • Serum

    • Urine

  • Collection Sites Outlook (Revenue, USD Million, 2016 - 2028)

    • Home

    • Office

    • Hospital

    • Diagnostic Labs

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • Spain

      • France

      • Italy

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Singapore

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • MEA

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.